Company intelligence / Profile preview

GQ Bio

Hamburg, Hamburg, Germanygqresearch.com ↗

Ownership: Private
Development stage: Other

Overview

GQ Bio developed a high-capacity adenoviral vector platform enabling efficient delivery of large or multiple genes. Their lead program, PCRX-201 (enekinragene inzadenovec), showed promising early clinical results in osteoarthritis. The company was acquired by Pacira to advance this technology for musculoskeletal diseases and potentially other indications requiring local genetic medicine delivery.

Therapeutic areas: Rheumatology
Modalities: Gene therapyAdenovirus-based gene therapy vector
Industry: Biotech

Partnerships

Pacira BioSciences partnership prior to acquisition focused on manufacturing process development for PCRX‑201 and other products using HCAd platform.Potential future outlicensing/partnerships outside Pacira’s core focus are suggested but not detailed.

Beyond the preview

Go deeper on GQ Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GQ Bio.

Explore the full profile